Detechgene, a Cologne-based biotech startup spun out of the University Hospital Cologne’s Nephrolab, has raised €3.2 million in seed funding to advance its portable molecular diagnostics platform.
The round was led by neoteq ventures, with participation from NRW.BANK, Aquarius Invest, Meerkat Holding, Campus Capital, and several angel investors.
PCR accuracy, rapid test simplicity
Founded in 2022 by Dr. Reza Esmaillie and Dr. Robin Bayer, Detechgene is developing a mobile diagnostic system that merges the accuracy of PCR with the ease of rapid antigen testing. Its cartridge-based technology allows users to detect pathogens quickly and reliably on-site, without needing lab equipment.
The company’s flagship solution, branded “PCR to Go”, provides precise results within minutes and is designed for a wide range of applications, from healthcare and emergency response to customised industry testing.
“Together with our investors, we are shaping the future of diagnostics — faster, more decentralised, and more user-friendly than ever before,” said Reza Esmaillie, Managing Director of Detechgene.
Advertisement
Decentralising diagnostics
The fresh funding will be used to scale product development, refine the cartridge platform, and pursue partnerships to bring customised testing solutions to market.
Backers highlight both the global relevance and the strong execution of the team. B.J. Park, Managing Partner at neoteq ventures, noted:
“Detechgene is tackling a global challenge with a solution that’s fast, mobile, and precise — without compromising the standards of laboratory diagnostics.”
With demand for portable, high-quality diagnostic solutions rising worldwide, Detechgene positions itself as part of the movement to make laboratory-grade testing accessible anywhere.
